Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study aimed to investigate the performance of innovative and traditional cardiometabolic indices, including body mass index (BMI), waist circumference (WC), Chinese visceral adiposity index (CVAI), visceral adiposity index, lipid accumulation product, a body shape index (ABSI), body roundness index, conicity index (CI), triglyceride-glucose (TyG) index, TyG-BMI, and TyG-WC, in estimating atherosclerotic cardiovascular disease (ASCVD) risk in 3143 Taiwanese adults aged 20-79 years. Elevated 10-year ASCVD risk was defined as ≥7.5% using the Pooled Cohort Equations. The performance of different indices in estimating elevated ASCVD risk was assessed by receiver operating characteristic (ROC) curves. In multivariate-adjusted logistic regression analyses, all cardiometabolic indices (-value < 0.001) were significantly associated with elevated ASCVD risk in both genders, except for ABSI and CI in women. In particular, CVAI had the largest area under the curve (AUC) in men (0.721) and women (0.883) in the ROC analyses. BMI had the lowest AUC in men (0.617), while ABSI had the lowest AUC in women (0.613). The optimal cut-off value for CVAI was 83.7 in men and 70.8 in women. CVAI performed best among various cardiometabolic indices in estimating elevated ASCVD risk. CVAI may be a reliable index for identifying people at increased risk of ASCVD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067018PMC
http://dx.doi.org/10.3390/diagnostics11040603DOI Listing

Publication Analysis

Top Keywords

ascvd risk
20
cardiometabolic indices
16
indices estimating
12
elevated ascvd
12
innovative traditional
8
traditional cardiometabolic
8
estimating atherosclerotic
8
atherosclerotic cardiovascular
8
cardiovascular disease
8
visceral adiposity
8

Similar Publications

Liraglutide is a key therapeutic agent in managing type 2 diabetes mellitus (T2DM), with benefits extending beyond glycemic control to address cardiovascular and renal comorbidities. As T2DM prevalence rises globally, the need for medications that provide comprehensive health benefits becomes increasingly important. Liraglutide, a GLP-1 receptor agonist, has demonstrated effectiveness in reducing cardiovascular events, especially among patients with high cardiovascular risk, such as those with a prior history of myocardial infarction or stroke.

View Article and Find Full Text PDF

Lipoprotein(a) at a "Tipping Point": case to move to universal screening.

Am J Prev Cardiol

September 2025

Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA, USA.

Elevated lipoprotein(a) [Lp(a)] is well established as a common risk factor for atherosclerotic cardiovascular disease (ASCVD). Lp(a) levels are >90 % genetically determined. However, Lp(a) remains very underrecognized as a cardiovascular risk factor with low rates of testing.

View Article and Find Full Text PDF

Background: Hispanics/Latinos are a heterogenous population with no validated atherosclerotic cardiovascular disease (ASCVD) risk estimation tool. We examined performance of the pooled cohort equation (PCE) across Hispanic/Latino background groups and quantiles of African, Amerindian, and European genetic ancestry.

Methods: The Multi-Ethnic Study of Atherosclerosis (MESA) was used to evaluate the performance of the non-Hispanic Black (NHB) and non-Hispanic White (NHW) PCE defined by predicted to observed (P/O) ratios of 10-year ASCVD events.

View Article and Find Full Text PDF

Background Medication adherence is mostly influenced by cost, and disease management can be achieved through cost-effective combinations. The present study aimed to evaluate adherence to the cost-effective fixed dose combination (FDC) of rosuvastatin and clopidogrel in the management of cardiovascular diseases (CVD). Methods This retrospective, non-randomized, non-comparative, multicenter study was conducted across 100 healthcare centers in India.

View Article and Find Full Text PDF

This systematic review evaluates the cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with type 2 diabetes mellitus (T2DM) and established atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure (HF). A comprehensive literature search across four major databases identified eight eligible studies, including randomized controlled trials and prespecified or pooled post-hoc analyses. The findings demonstrate consistent cardiovascular benefits of GLP-1 RAs, particularly semaglutide and exenatide, with notable reductions in major adverse cardiovascular events, cardiovascular mortality, and HF-related outcomes.

View Article and Find Full Text PDF